ArticleClinical cardiology2025
Epicardial Fat Thickness as a Marker of Coronary Artery Disease in Diabetics: A Single Center Study.
Article in Clinical cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Comment on "Epicardial Fat Thickness as a Marker of Coronary Artery Disease in Diabetics: A Single Center Study".Clinical cardiology · 2026Article
- Critique on "Epicardial Fat Thickness as a Marker of Coronary Artery Disease in Diabetics: A Single Center Study".Clinical cardiology · 2026Article
- Epicardial adipose tissue mediates the association between circulating hsa-miR-4750-3p and coronary artery disease in patients with type 2 diabetes mellitus.Cardiovascular diabetology · 2026Observational
- Epicardial Fat Thickness as a Marker of Coronary Artery Disease Severity and Ischemic Burden: A Prospective Echocardiographic Study.Journal of clinical medicine · 2026Article
- Association of the Triglyceride Glucose Index and Epicardial Adipose Tissue with Type 2 Diabetes Mellitus Complicated by Coronary Atherosclerotic Heart Disease.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Concerns and Considerations Regarding the Study on Epicardial Fat Thickness as a Marker for Coronary Artery Disease in Diabetic Patients.Clinical cardiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEpicardial fat thickness (EFT) is a visceral fat depot with pro-inflammatory properties, located adjacent to coronary vessels, and has been proposed as a marker of coronary artery disease (CAD). This study aimed to evaluate the association between EFT and the presence and severity of CAD in patients with type 2 diabetes mellitus.
methodsThis retrospective study was conducted at the Abbas Institute of Medical Sciences (AIMS) between January 2020 and March 2025 (Study ID: AIMS/25/007). A total of 2340 diabetic patients (mean age: 58.3 ± 9.6 years) were included. EFT was measured using transthoracic echocardiography, and CAD presence and severity were assessed via coronary angiography. Logistic regression analysis was used to evaluate associations, with results expressed as odds ratios (OR) with 95% confidence intervals (CI).
resultsElevated EFT (≥ 5 mm) was observed in 1281 patients (54.7%). CAD was present in 1121 individuals (47.9%), with significantly higher rates in those with elevated EFT (65.7% vs. 26.3%, p < 0.001). EFT ≥ 5 mm was associated with a 5.38-fold increased odds of CAD (95% CI: 4.59-6.30, p < 0.001). Moreover, patients with elevated EFT had a significantly higher prevalence of multi-vessel CAD, indicating a correlation between EFT and disease severity.
conclusionsIn diabetic patients, elevated EFT is significantly associated with both the presence and severity of CAD. EFT measurement via echocardiography may serve as a simple, noninvasive tool for cardiovascular risk stratification and early intervention planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.